West Pharmaceutical Services Inc. (NYSE:WST) has received a consensus rating of “Hold” from the six research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $101.50.
WST has been the subject of several recent analyst reports. Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $110.00 target price for the company in a research report on Saturday, June 30th. ValuEngine upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Tuesday, June 12th.
In other West Pharmaceutical Services news, SVP Karen Flynn sold 20,458 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, August 7th. The stock was sold at an average price of $116.23, for a total value of $2,377,833.34. Following the transaction, the senior vice president now owns 31,051 shares in the company, valued at $3,609,057.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is owned by insiders.
NYSE WST opened at $120.03 on Tuesday. The company has a current ratio of 2.67, a quick ratio of 1.94 and a debt-to-equity ratio of 0.15. West Pharmaceutical Services has a 12 month low of $82.74 and a 12 month high of $121.14. The company has a market cap of $8.85 billion, a price-to-earnings ratio of 43.18, a PEG ratio of 4.08 and a beta of 1.20.
West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 26th. The medical instruments supplier reported $0.70 EPS for the quarter, topping the consensus estimate of $0.67 by $0.03. The company had revenue of $447.50 million during the quarter, compared to analyst estimates of $422.57 million. West Pharmaceutical Services had a net margin of 8.99% and a return on equity of 15.38%. West Pharmaceutical Services’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.66 earnings per share. analysts expect that West Pharmaceutical Services will post 2.82 earnings per share for the current year.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.